Related Experiment Videos
A pilot study of parenteral lincomycin therapy in soft tissue infections
R S Greval1, S C Goyal, J R Sofat
1Dept. of ENT, Dayanand Medical College and Hospital Ludhiana.
Abstract:
From our study it is clear that lincomycin, given 300 mg intra muscularly daily in a single dose, is effective in a wide range of soft tissue infections especially those involving the head and neck region. An overall success rate of 88.8 per cent was observed in the 150 patients selected for the study. It is significant that in none of the subjects was any untoward reaction observed or reported. Hitherto all the previous systematic surveys on lincomycin appear to have been carried out on bone infections where, undoubtedly, lincomycin is highly effective. This pilot study furnishes an encouraging report on the successful treatment of soft tissue infections with parenteral lincomycin.
Insights
Lincomycin effectively treats soft tissue infections, particularly in the head and neck region, with an 88.8% success rate. This study found no adverse reactions in patients receiving daily intramuscular lincomycin injections.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Medicine
Background:
- Lincomycin is established as effective for bone infections.
- Limited data exists on lincomycin's efficacy for soft tissue infections.
Purpose of the Study:
- To evaluate the effectiveness and safety of lincomycin in treating soft tissue infections.
- To investigate lincomycin's utility in head and neck soft tissue infections.
Main Methods:
- A pilot study involving 150 patients with soft tissue infections.
- Lincomycin administered intramuscularly at 300 mg daily in a single dose.
Main Results:
- An overall success rate of 88.8% was observed.
- The treatment was particularly effective for head and neck soft tissue infections.
- No adverse reactions were reported in any of the study subjects.
Conclusions:
- Parenteral lincomycin is an effective treatment for a variety of soft tissue infections.
- Lincomycin demonstrates a favorable safety profile for treating soft tissue infections.
- Further research into parenteral lincomycin for soft tissue infections is warranted.